Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://shintaros468tmh8.luwebs.com/profile